Search

for
Search:

GlossaryRituximab

monoclonal antibody targeting CD20 protein on B-cells

Rituximab, also known as Rituxan, is a monoclonal antibody used to treat certain autoimmune diseases and types of cancer, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It works by targeting and binding to the CD20 protein found on the surface of B-cells, leading to their destruction, which helps in reducing the abnormal immune response or cancerous growth.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 330 results

research Case Report: Extensive Digital Gangrene as a Primary Manifestation of Late-Onset Systemic Lupus Erythematosus

August 2022 in “F1000Research”

Digital gangrene can be a rare first sign of late-onset systemic lupus erythematosus.

research Frontal Fibrosing Alopecia: An Update on Epidemiology and Treatment

7 citations , October 2015 in “Actas Dermo-Sifiliográficas”

New treatments for Frontal Fibrosing Alopecia show promise, especially finasteride and dutasteride, with most patients seeing improvement or stabilization.

$Refractory/Relapse Thrombocytopenia in a Patient With Evans' Syndrome Successfully Treated With Zanubrutinib$

research Refractory/Relapse Thrombocytopenia in a Patient With Evans' Syndrome Successfully Treated With Zanubrutinib

2 citations , October 2022 in “British journal of haematology”

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

research The Efficacy of Spiritual Healing

1 citations , June 2001 in “Annals of Internal Medicine”

The document concludes that there is no credible evidence that distant healing works, and it should not be further studied in medical literature.

research Herpes Simplex Virus Infection in Pemphigus Patients: A Prospective Study

October 2021 in “The journal of investigative dermatology/Journal of investigative dermatology”

Herpes simplex virus infections should be considered in pemphigus patients to avoid unnecessary changes in treatment.

View more "rituximab" in research →

Community Join

0 / 0 results

— no results